Psilocybin as a Treatment for Chronic Pain in Smokers
Early-phase psilocybin study for veterans who smoke and have chronic pain, testing pain relief and smoking cessation together. This is not a PTSD study — current or past PTSD is an exclusion criterion.
This is an interventional study — the research team administers the treatment under a controlled, IRB-approved protocol. Participation never happens outside that protocol.
- Substance
- Psilocybin
- Status
- Recruiting now
- Conditions
- Chronic Pain, Smoking Cessation
- Who can join
- Veterans 21–65 with chronic pain who smoke — current/past PTSD excludes eligibility
- Where
- Connecticut
- Run by
- Yale University
- Registry ID
- NCT07118332 ↗
How to join this study
Call or email the study team directly. You do not go through Psychedelic Vets — we just make the door easier to find.
Contact details as published by the sponsor, last verified 2026-07. People move on — if this doesn't reach anyone, check ClinicalTrials.gov.
What taking part involves
Who can join
Listed as the research team wrote them. This is not a decision about you — only the study team can say whether you are eligible, and the only way to find out is to ask them.
What the study is looking for
- Veterans aged 21 to 65 years, who have been smoking tobacco cigarettes daily cigarettes for at least a year (confirmed with urine cotinine strips indicating smoking status (28)
- not seeking treatment at the time of the study for tobacco use.
- endorsement of bothersome or high-impact chronic non-cancer pain per the Graded Pain Scale - Revised (29);
- in good health as verified by medical history, screening examination, and screening laboratory tests; and
- body mass index (BMI) between 18 to 35 because there is limited information on the safety of psilocybin in individuals outside this range.
- for women, not pregnant as determined by pregnancy screening, nor breastfeeding, and using acceptable birth control methods (e.g., oral contraceptives).
What would rule you out
- History of major medical disorders (e.g., diabetes, epilepsy, kidney or liver diseases, heart rhythm problems, heart failure, hypertension with BP greater than 140/90mmHg, history of cerebrovascular problems, severe asthma, etc.).
- lifetime history of schizophrenia, bipolar disorder, dissociative disorders, or borderline personality disorder, current major depressive episode, or PTSD.
- first- or second-degree relatives with a history of bipolar disorder or schizophrenia.
- suicide attempt or ideation in the past year.
- regular use of certain psychotropic medications (antidepressants, antipsychotics, mood stabilizers or anxiolytics) that are deemed to have the potential for adverse effects or drug reactions with psilocybin including SSRIs and MAO inhibitors.
- current untreated moderate or severe substance use disorder for any other recreational or prescription drugs other than nicotine.
- known sensitivity or intolerability to psilocybin.
You enroll directly with the research team through their own official page and IRB-approved consent process. Psychedelic Vets does not run this study or collect any of your health information.
Study data is sourced from ClinicalTrials.gov (U.S. National Library of Medicine) and verified university/nonprofit sources. This page is educational and is not medical advice or an endorsement. Details can change — always confirm on the official page above. ← Back to all studies
